Please enable JavaScript to continue using this application.

Compare $KRYS vs $PTGX | Chartloom

Compare

$KRYS vs $PTGX

Krystal Biotech Inc · Protagonist Therapeutics Inc

KRYS

Krystal Biotech Inc

PTGX

Protagonist Therapeutics Inc

Compare $KRYS vs $PTGX

Comparing Krystal Biotech Inc and Protagonist Therapeutics Inc

KRYSKrystal Biotech Inc

PTGXProtagonist Therapeutics Inc

KRYSKrystal Biotech Inc

Market cap

$9.78B

P/E (TTM)

42.10x

Forward P/E (NTM)

39.13x

Forward P/S (NTM)

16.80x

Rev growth (TTM)

22.6%

YTD performance

34.3%

52W performance

77.2%

FCF yield

2.6%

PTGXProtagonist Therapeutics Inc

Market cap

$9.24B

P/E (TTM)

123.10x

Forward P/E (NTM)

77.71x

Forward P/S (NTM)

23.74x

Rev growth (TTM)

34.8%

YTD performance

64.9%

52W performance

120.1%

FCF yield

1.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KRYS

PTGX

Detailed metrics comparison

KRYS

Krystal Biotech Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

KRYS$9.78B

PTGX$9.24B

Enterprise Value

KRYS$9.35B

PTGX$8.82B

Price

KRYS$331.61

PTGX$143.73

P/E Ratio

KRYS42.10x

PTGX123.10x

P/S Ratio

KRYS22.19x

PTGX32.78x

EV/Sales

KRYS21.22x

PTGX31.29x

EV/EBITDA

KRYS42.60x

PTGX140.17x

P/B Ratio

KRYS7.02x

PTGX10.77x

P/FCF Ratio

KRYS37.92x

PTGX70.79x

EV/FCF

KRYS36.26x

PTGX67.57x

PEG Ratio

KRYS1.01x

PTGX2.95x

Forward P/E (NTM)

KRYS39.13x

PTGX77.71x

Forward P/S (NTM)

KRYS16.80x

PTGX23.74x

Revenue (TTM)

KRYS$440M

PTGX$282M

Revenue Growth (YoY)

KRYS22.6%

PTGX34.8%

Forward Rev Growth

KRYS27.8%

PTGX-70.6%

Gross Margin (TTM)

KRYS94.6%

PTGX0.0%

Operating Margin (TTM)

KRYS44.9%

PTGX20.7%

EBITDA Margin (TTM)

KRYS46.2%

PTGX21.2%

Net Margin (TTM)

KRYS54.8%

PTGX29.4%

FCF Margin (TTM)

KRYS58.5%

PTGX46.3%

Net Income (TTM)

KRYS$241M

PTGX$83M

FCF (TTM)

KRYS$258M

PTGX$131M

EPS (TTM)

KRYS$7.88

PTGX$1.17

ROE (TTM)

KRYS19.3%

PTGX12.0%

ROA (TTM)

KRYS17.6%

PTGX11.2%

ROIC (TTM)

KRYS19.3%

PTGX12.0%

Cash

KRYS$428M

PTGX$420M

Debt

KRYS$0

PTGX$0

Net Cash/Debt

KRYS$428M

PTGX$420M

Current Ratio (TTM)

KRYS8.32x

PTGX21.71x

Quick Ratio (TTM)

KRYS7.73x

PTGX21.58x

Debt/Equity (TTM)

KRYS0.00x

PTGX0.00x

Debt/Assets (TTM)

KRYS0.0%

PTGX0.0%

Interest Coverage (TTM)

KRYSN/A

PTGXN/A

Net Debt/EBITDA (TTM)

KRYS0.00x

PTGX0.00x

Beta

KRYS0.65

PTGX1.19

52W Performance

KRYS77.2%

PTGX120.1%

YTD Performance

KRYS34.3%

PTGX64.9%

% from 52W High

KRYS-13.3%

PTGX-10.6%

% from 52W Low

KRYS85.1%

PTGX119.2%

Asset Turnover (TTM)

KRYS0.32x

PTGX0.38x

FCF Yield (TTM)

KRYS2.6%

PTGX1.4%

Earnings Yield (TTM)

KRYS2.5%

PTGX0.9%

Dividend Yield (TTM)

KRYSN/A

PTGXN/A

Rule of 40

KRYS81.1

PTGX81.1

EV/GP/RG

KRYS0.65

PTGXN/A

Ticker research

View KRYS research View PTGX research

Metric	KRYS Krystal Biotech Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$9.78B	$9.24B
Enterprise Value	$9.35B	$8.82B
Price	$331.61	$143.73
P/E Ratio	42.10x	123.10x
P/S Ratio	22.19x	32.78x
EV/Sales	21.22x	31.29x
EV/EBITDA	42.60x	140.17x
P/B Ratio	7.02x	10.77x
P/FCF Ratio	37.92x	70.79x
EV/FCF	36.26x	67.57x
PEG Ratio	1.01x	2.95x
Forward P/E (NTM)	39.13x	77.71x
Forward P/S (NTM)	16.80x	23.74x
Revenue & Growth
Revenue (TTM)	$440M	$282M
Revenue Growth (YoY)	22.6%	34.8%
Forward Rev Growth	27.8%	-70.6%
Profitability
Gross Margin (TTM)	94.6%	0.0%
Operating Margin (TTM)	44.9%	20.7%
EBITDA Margin (TTM)	46.2%	21.2%
Net Margin (TTM)	54.8%	29.4%
FCF Margin (TTM)	58.5%	46.3%
Net Income (TTM)	$241M	$83M
FCF (TTM)	$258M	$131M
EPS (TTM)	$7.88	$1.17
ROE (TTM)	19.3%	12.0%
ROA (TTM)	17.6%	11.2%
ROIC (TTM)	19.3%	12.0%
Financial Health
Cash	$428M	$420M
Debt	$0	$0
Net Cash/Debt	$428M	$420M
Current Ratio (TTM)	8.32x	21.71x
Quick Ratio (TTM)	7.73x	21.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.65	1.19
52W Performance	77.2%	120.1%
YTD Performance	34.3%	64.9%
% from 52W High	-13.3%	-10.6%
% from 52W Low	85.1%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.32x	0.38x
FCF Yield (TTM)	2.6%	1.4%
Earnings Yield (TTM)	2.5%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	81.1
EV/GP/RG	0.65	N/A
Ticker research	View KRYS research	View PTGX research

Valuation

P/E Ratio

KRYS

42.10x

PTGX

123.10x

P/S Ratio

KRYS

22.19x

PTGX

32.78x

EV/FCF

KRYS

36.26x

PTGX

67.57x

Growth & revenue

Revenue Growth TTM

PTGX

34.8%

KRYS

22.6%

Forward Revenue Growth

KRYS

27.8%

PTGX

-70.6%

Profitability & performance

Gross Margin

KRYS

94.6%

PTGX

0.0%

ROE

KRYS

19.3%

PTGX

12.0%

FCF Yield %

KRYS

2.6%

PTGX

1.4%

52-Week Performance

PTGX

120.1%

KRYS

77.2%

Detailed metrics comparison

KRYS

Krystal Biotech Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

KRYS$9.78B

PTGX$9.24B

Enterprise Value

KRYS$9.35B

PTGX$8.82B

Price

KRYS$331.61

PTGX$143.73

P/E Ratio

KRYS42.10x

PTGX123.10x

P/S Ratio

KRYS22.19x

PTGX32.78x

EV/Sales

KRYS21.22x

PTGX31.29x

EV/EBITDA

KRYS42.60x

PTGX140.17x

P/B Ratio

KRYS7.02x

PTGX10.77x

P/FCF Ratio

KRYS37.92x

PTGX70.79x

EV/FCF

KRYS36.26x

PTGX67.57x

PEG Ratio

KRYS1.01x

PTGX2.95x

Forward P/E (NTM)

KRYS39.13x

PTGX77.71x

Forward P/S (NTM)

KRYS16.80x

PTGX23.74x

Revenue (TTM)

KRYS$440M

PTGX$282M

Revenue Growth (YoY)

KRYS22.6%

PTGX34.8%

Forward Rev Growth

KRYS27.8%

PTGX-70.6%

Gross Margin (TTM)

KRYS94.6%

PTGX0.0%

Operating Margin (TTM)

KRYS44.9%

PTGX20.7%

EBITDA Margin (TTM)

KRYS46.2%

PTGX21.2%

Net Margin (TTM)

KRYS54.8%

PTGX29.4%

FCF Margin (TTM)

KRYS58.5%

PTGX46.3%

Net Income (TTM)

KRYS$241M

PTGX$83M

FCF (TTM)

KRYS$258M

PTGX$131M

EPS (TTM)

KRYS$7.88

PTGX$1.17

ROE (TTM)

KRYS19.3%

PTGX12.0%

ROA (TTM)

KRYS17.6%

PTGX11.2%

ROIC (TTM)

KRYS19.3%

PTGX12.0%

Cash

KRYS$428M

PTGX$420M

Debt

KRYS$0

PTGX$0

Net Cash/Debt

KRYS$428M

PTGX$420M

Current Ratio (TTM)

KRYS8.32x

PTGX21.71x

Quick Ratio (TTM)

KRYS7.73x

PTGX21.58x

Debt/Equity (TTM)

KRYS0.00x

PTGX0.00x

Debt/Assets (TTM)

KRYS0.0%

PTGX0.0%

Interest Coverage (TTM)

KRYSN/A

PTGXN/A

Net Debt/EBITDA (TTM)

KRYS0.00x

PTGX0.00x

Beta

KRYS0.65

PTGX1.19

52W Performance

KRYS77.2%

PTGX120.1%

YTD Performance

KRYS34.3%

PTGX64.9%

% from 52W High

KRYS-13.3%

PTGX-10.6%

% from 52W Low

KRYS85.1%

PTGX119.2%

Asset Turnover (TTM)

KRYS0.32x

PTGX0.38x

FCF Yield (TTM)

KRYS2.6%

PTGX1.4%

Earnings Yield (TTM)

KRYS2.5%

PTGX0.9%

Dividend Yield (TTM)

KRYSN/A

PTGXN/A

Rule of 40

KRYS81.1

PTGX81.1

EV/GP/RG

KRYS0.65

PTGXN/A

Ticker research

View KRYS research View PTGX research

Metric	KRYS Krystal Biotech Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$9.78B	$9.24B
Enterprise Value	$9.35B	$8.82B
Price	$331.61	$143.73
P/E Ratio	42.10x	123.10x
P/S Ratio	22.19x	32.78x
EV/Sales	21.22x	31.29x
EV/EBITDA	42.60x	140.17x
P/B Ratio	7.02x	10.77x
P/FCF Ratio	37.92x	70.79x
EV/FCF	36.26x	67.57x
PEG Ratio	1.01x	2.95x
Forward P/E (NTM)	39.13x	77.71x
Forward P/S (NTM)	16.80x	23.74x
Revenue & Growth
Revenue (TTM)	$440M	$282M
Revenue Growth (YoY)	22.6%	34.8%
Forward Rev Growth	27.8%	-70.6%
Profitability
Gross Margin (TTM)	94.6%	0.0%
Operating Margin (TTM)	44.9%	20.7%
EBITDA Margin (TTM)	46.2%	21.2%
Net Margin (TTM)	54.8%	29.4%
FCF Margin (TTM)	58.5%	46.3%
Net Income (TTM)	$241M	$83M
FCF (TTM)	$258M	$131M
EPS (TTM)	$7.88	$1.17
ROE (TTM)	19.3%	12.0%
ROA (TTM)	17.6%	11.2%
ROIC (TTM)	19.3%	12.0%
Financial Health
Cash	$428M	$420M
Debt	$0	$0
Net Cash/Debt	$428M	$420M
Current Ratio (TTM)	8.32x	21.71x
Quick Ratio (TTM)	7.73x	21.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.65	1.19
52W Performance	77.2%	120.1%
YTD Performance	34.3%	64.9%
% from 52W High	-13.3%	-10.6%
% from 52W Low	85.1%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.32x	0.38x
FCF Yield (TTM)	2.6%	1.4%
Earnings Yield (TTM)	2.5%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	81.1
EV/GP/RG	0.65	N/A
Ticker research	View KRYS research	View PTGX research